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Edited by Michael R. BubbAbstract Human neutrophils underwent spontaneous apoptosis,
which was accompanied by degradation of Mcl-1, but not other
anti-apoptotic molecules (cIAP1, cIAP2, A1, survivin and Bcl-
2). Spontaneous neutrophil apoptosis and Mcl-1 degradation
were prevented by cyclic AMP (cAMP) agonists (dibutyryl
cAMP and prostaglandin E1), and the eﬀects of cAMP agonists
on neutrophils were highly resistant to cycloheximide, a protein
synthesis inhibitor, although slight increase in Mcl-1 mRNA
expression was induced by cAMP agonists. Proteasome inhibi-
tors (epoxomicin and lactacystin) also prevented spontaneous
neutrophil apoptosis and Mcl-1 degradation to the same extent
as cAMP agonists, and no additive eﬀect was obtained by com-
bination of cAMP agonists and proteasome inhibitors. These
ﬁndings suggest that cAMP agonists, like proteasome inhibitors,
delay neutrophil apoptosis primarily via stabilization of Mcl-1.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Neutrophils1. Introduction
Neutrophils are short-lived cells as a result of immediate cell
death by spontaneous apoptosis. Spontaneous neutrophil
apoptosis is delayed in the presence of various cytokines and
chemical agents, including granulocyte colony-stimulating fac-
tor (G-CSF), granulocyte-macrophage CSF (GM-CSF), and
dibutyryl cyclic AMP (cAMP) [1–5]. Modulation of neutrophil
apoptosis by cytokines or chemical mediators produced at
inﬂammatory sites may be closely associated with the outcome
of inﬂammation. However, neither the mechanism regulating
spontaneous neutrophil apoptosis nor the mechanism by
which cytokines and chemical agents exert the anti-apoptotic
eﬀect on neutrophils are fully understood. Possibilities may in-
clude up- or downregulation of molecules associated with
apoptosis, which may include the Bcl-2 family (Mcl-1, A1,Abbreviations: cAMP, cyclic AMP; ECL, enhanced chemilumines-
cence; ERK, extracellular signal-regulated kinase; G-CSF, granulocyte
colony-stimulating factor; GM-CSF, granulocyte-macrophage CSF;
IAP, inhibitor of apoptosis; PCR, polymerase chain reaction; PGE1,
prostaglandin E1; PI, propidium iodide; PI3K, phosphatidylinositol 3-
kinase; PKA, cAMP-dependent protein kinase
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doi:10.1016/j.febslet.2006.07.034Bcl-XL and Bax) and the inhibitor of apoptosis (IAP) family
(cIAP1, cIAP2, XIAP and survivin) proteins [1–3,6]. For
example, it has been reported that G-CSF upregulates the
expression of cIAP2, survivin and A1 [1,7,8]. GM-CSF upreg-
ulates the expression of Mcl-1 and survivin [2,3,7]. Interferon-a
and c upregulate the expression of cIAP2 [9]. Although it has
been demonstrated that cAMP exerts the anti-apoptotic eﬀect
on human neutrophils via cAMP-dependent protein kinase
(PKA) [5], the targets of cAMP action remain to be deter-
mined. Our recent study shows that cAMP exerts the anti-
apoptotic eﬀect on human neutrophils, in large part, through
the protein synthesis-independent mechanism [4]. This ﬁnding
raises the possibility that cAMP may stabilize certain anti-
apoptotic molecules, leading to delayed neutrophil apoptosis.
Here, we show that, among anti-apoptotic molecules studied,
only Mcl-1 is degraded during spontaneous neutrophil apopto-
sis, and Mcl-1 is stabilized by cAMP agonists and proteasome
inhibitors with concomitant delay of neutrophil apoptosis.2. Materials and methods
2.1. Materials
Dibutyryl cAMP and cycloheximide were purchased from Sigma
Chemical Co. (St. Louis, MO). Prostaglandin E1 (PGE1), epoxomicin,
and clasto-lactacystin b-lactone were purchased from Calbiochem (La
Jolla, CA). Conray was purchased fromMallinckrodt (St. Louis, MO).
Ficoll was purchased from Pharmacia Fine Chemicals (Piscataway,
NJ). Rabbit polyclonal antibody against Mcl-1 was purchased from
BD PharMingen (San Diego, CA). Rabbit polyclonal antibodies
against cIAP1, cIAP2 and A1 were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Mouse monoclonal antibody against
survivin, rabbit polyclonal antibody against p38 mitogen-activated
protein kinase, and goat anti-rabbit or anti-mouse IgG antibody con-
jugated with horseradish peroxidase were purchased from Cell Signal-
ing Technology (Beverley, MA). The enhanced chemiluminescence
(ECL) Western blotting system was purchased from Amersham Phar-
macia Biotech (Buckinghamshire, England). Annexin V-FITC apopto-
sis detection kit was purchased from MBL (Nagoya, Japan).
2.2. Preparation of cells
Human neutrophils were prepared from healthy adult donors as de-
scribed previously [1], using dextran sedimentation, centrifugation with
Conray-Ficoll, and hypotonic lysis of contaminating erythrocytes.
Cells were suspended in Hanks’ balanced salt solution containing
10 mM N-2-hydroxyethyl-piperazine-N 0-2-ethane-sulfonic acid (pH
7.4). Neutrophil fractions contained >98% neutrophils.
2.3. Determination of apoptosis
Neutrophils (5 · 106 cells/ml) were incubated in the presence or
absence of dibutyryl cAMP (1 mM), PGE1 (100 nM), epoxomicin
(1 lM), lactacystin (5 lM), cycloheximide (10 lg/ml), or combination
of these agents for 8 h at 37 C. Theophylline (0.2 mM) was always
added with PGE1. Cells were stained with annexin V-FITC and
propidium iodide (PI), and apoptotic cells were determined by ﬂowblished by Elsevier B.V. All rights reserved.
Fig. 1. cAMP agonists prevent spontaneous neutrophil apoptosis.
Neutrophils were incubated in the presence or absence of dibutyryl
cAMP (db-cAMP, 1 mM), PGE1 (100 nM), cycloheximide (CHX,
10 lg/ml), or combination of these agents for 8 h at 37 C. Apoptotic
cells were analyzed by ﬂow cytometry. The data are expressed as
means ± S.E.M. of three independent experiments. +Signiﬁcantly
greater as compared with 0 h controls (P < 0.01). *Spontaneous
apoptosis was signiﬁcantly prevented by dibutyryl cAMP or PGE1
(P < 0.01). #Spontaneous apoptosis was signiﬁcantly accelerated by
cycloheximide (P < 0.01).
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positive, PI-negative cells were considered as apoptotic cells. DNA
content was also determined by PI staining and ﬂow cytometry.
Hypodiploid cells were considered as cells undergoing apoptosis-
associated DNA degradation [1,9].
2.4. Western blotting
Western blotting was performed as described previously [1,9]. Cells
were ﬁxed by 10% trichloroacetic acid, and were washed with acetone
containing 10 mM dithiothreitol. The cells were lysed with 1· sample
buﬀer (2% sodium dodecyl sulfate (SDS), 10% glycerol, 5% 2-mercap-
toethanol, and a trace amount of bromophenol blue dye in 62.5 mM
Tris–HCl, pH 6.8), and were boiled for 5 min. Samples were subjected
to 4–20% gradient SDS gel electrophoresis. After electrophoresis, pro-
teins were electrophoretically transferred from the gel onto a nitrocel-
lulose membrane in a buﬀer containing 100 mM Tris, 192 mM glycine
and 20% methanol at 2 mA/cm2 for 1 h at room temperature. Residual
binding sites on the membrane were blocked by incubating the mem-
brane in Tris-buﬀered saline (pH 7.6) containing 5% non-fat dry milk
for 1 h at room temperature. The blots were incubated with appropri-
ate primary antibody overnight at 4 C. After washing, the membrane
was incubated with appropriate secondary antibody conjugated with
horseradish peroxidase, and the antibody complexes were visualized
by the ECL detection system as directed by the manufacturer. Immu-
noreactive bands were quantiﬁed by the NIH Image program on a
Macintosh computer.
2.5. Real-time polymerase chain reaction (PCR) analysis
The real-time PCR analysis was performed with LightCycler (Roche
Molecular Biochemicals, Mannheim, Germany) as described previ-
ously [1,4]. The reaction mixtures (20 ll) contained MgCl2 (3 mM),
the forward and reverse primers (0.5 lM), the ﬂuorescein isothiocya-
nate (FITC)-conjugated probe (0.2 lM), LightCycler Red 640 (LC
Red 640)-conjugated probe (0.4 lM), LightCycler-DNA master
hybridization probe (0.4 lM), and cDNA (1 ll). As an internal con-
trol, 18S rRNA was used. The primer sequences and the hybridization
probe sets were as follows. Mcl-1: forward primer, 5 0-CTC TCA TTT
CTT TTG GTG CCT-3 0; reverse primer, 5 0-ATT CCT GAT GCC
ACC TTC TA-3 0; hybridization probe sets, 5 0-GTT CTC GTA
AGG ACA AAA CGG GAC T-[FITC]-3 0 and 5 0-[LC Red 640]-
GCT AGT TAA ACA AAG AGG CTG GGA TG-[phosphate]-3 0.
18 S rRNA: forward primer, 5 0-TCC GAT AAC GAA CGA GAC
TC-30; reverse primer, 5 0-CAG GGA CTT AAT CAA CGC AA-3 0;
hybridization probe sets, 5 0-GGA CAT CTA AGG GCA TCA
CAG ACC T-[FITC]-3 0 and 5 0-[LC Red 640]-TTA TTG CTC AAT
CTC GGG TGG CT-[phosphate]-3 0.
2.6. Statistical analysis
Student’s t test was used to determine statistical signiﬁcance.3. Results
Human neutrophils underwent spontaneous apoptosis dur-
ing culture of 8 h, and spontaneous neutrophil apoptosis was
accelerated in the presence of cycloheximide, a protein synthe-
sis inhibitor (Fig. 1) [4,9]. Spontaneous neutrophil apoptosis
was signiﬁcantly delayed in the presence of dibutyryl cAMP
or PGE1 (Fig. 1). The anti-apoptotic eﬀect of dibutyryl cAMP
or PGE1 was unaﬀected by cycloheximide, indicating that
cAMP agonists exert the anti-apoptotic eﬀect on neutrophils
through the protein synthesis-independent mechanism [4,10].
As shown in Fig. 2A, the level of Mcl-1 protein was dramat-
ically decreased during 8 h culture, which was accelerated in
the presence of cycloheximide. The decrease in Mcl-1 protein
during culture was prevented in the presence of dibutyryl
cAMP or PGE1 (Fig. 2A). This eﬀect of dibutyryl cAMP or
PGE1 was unaﬀected by cycloheximide, indicating that cAMP
preserve the level of Mcl-1 protein by preventing degradation
of the protein. To explore the possibility that cAMP agonistsmight induce Mcl-1 mRNA expression, the real-time PCR
analysis was performed. As shown in Fig. 2B, dibutyryl cAMP
or PGE1 induced slight increase in Mcl-1 mRNA expression,
which was apparent at 1 h after incubation. However, under
the conditions studied, the level of Mcl-1 protein was not sig-
niﬁcantly aﬀected by cycloheximide in the presence of dibuty-
ryl cAMP or PGE1 (Fig. 2A).
As shown in Fig. 3, the level of other anti-apoptotic mole-
cules, including cIAP1, cIAP2, A1, survivin and Bcl-2, was
not signiﬁcantly altered during spontaneous apoptosis induced
by 8 h culture alone. In addition, the level of all these mole-
cules during culture was unaﬀected by the presence of cyclo-
heximide, dibutyryl cAMP or PGE1 (Fig. 3). These ﬁndings
suggest that cAMP agonists delay spontaneous neutrophil
apoptosis by stabilization of Mcl-1, but not other anti-apopto-
tic molecules.
It has been reported that Mcl-1 is rapidly degraded by the
proteasome, and proteasome inhibitors delay neutrophil spon-
taneous apoptosis by stabilization of Mcl-1 [11]. We conﬁrmed
this observation by using epoxomicin and lactacystin as pro-
teasome inhibitor (Fig. 4). Proteasome inhibitors delayed neu-
trophil apoptosis to the same extent as dibutyryl cAMP, and
the anti-apoptotic eﬀect of combination of dibutyryl cAMP
and a proteasome inhibitor (epoxomicin or lactacystin) was
identical to that of either agent alone. Consistent with these
ﬁndings, proteasome inhibitors prevented Mcl-1 degradation
Fig. 2. cAMP agonists prevent degradation of Mcl-1 protein and
induce Mcl-1 mRNA expression. (A) Neutrophils were incubated in
the presence or absence of dibutyryl cAMP (db-cAMP, 1 mM), PGE1
(100 nM), cycloheximide (CHX, 10 lg/ml), or combination of these
agents for 8 h at 37 C. Immunoblotting was performed using
antibodies against Mcl-1 and p38, which was used as control. The
cell lysates equivalent to 5 · 105 cells were loaded onto each lane. The
results shown are representative of three independent experiments
(upper panel). The densitometric data are expressed as means ± S.E.M.
of three independent experiments (lower panel). The ratio of Mcl-1 to
p38 band intensity was calculated, and the ratio at hour 0 is expressed
as 1. +Signiﬁcantly decreased as compared with 0 h controls (P < 0.01).
*Mcl-1 degradation was signiﬁcantly prevented by dibutyryl cAMP or
PGE1 (P < 0.01).
#Mcl-1 degradation was signiﬁcantly accelerated by
cycloheximide (P < 0.05). (B) Neutrophils were incubated in the
presence or absence of dibutyryl cAMP (db-cAMP, 1 mM), or PGE1
(100 nM) for 1–4 h at 37 C. Mcl-1 mRNA expression was analyzed by
the real-time PCR. As an internal control, 18S rRNA was used. The
ratio of Mcl-1 to 18S rRNA was calculated, and the ratio at hour 0 is
expressed as 1. The data are expressed as the means ± S.E.M. of three
independent experiments. *
,
**Signiﬁcantly increased as compared with
control cells (*P < 0.05, **P < 0.01). +Signiﬁcantly increased as com-
pared with 0 h controls (P < 0.05).
Fig. 3. No degradation of cIAP1, cIAP2, A1, survivin and Bcl-2
during culture. Neutrophils were incubated in the presence or absence
of dibutyryl cAMP (db-cAMP, 1 mM), PGE1 (100 nM), cycloheximide
(CHX, 10 lg/ml), or combination of these agents for 8 h at 37 C.
Immunoblotting was performed using antibodies against cIAP1,
cIAP2, A1, survivin and Bcl-2. The cell lysates equivalent to 5 · 105
cells were loaded onto each lane. The lysates of HL-60 cells (2.5 · 105
cells), a human myelogenous leukemia cell line, were used as controls.
The results shown are representative of three independent experiments.
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prevention of Mcl-1 degradation by combination of dibutyryl
cAMP and a proteasome inhibitor (epoxomicin or lactacystin)
was identical to that by either agent alone (Fig. 5). These ﬁnd-
ings indicate that neutrophil apoptosis is closely associated
with the altered level of Mcl-1 protein, and suggest that cAMP
agonists, like proteasome inhibitors, prevent neutrophil apop-
tosis by stabilization of Mcl-1.It has been reported that GM-CSF exerts the anti-apoptotic
eﬀect on human neutrophils through both induction of Mcl-1
protein synthesis and stabilization of Mcl-1 protein, and that
GM-CSF-induced stabilization of Mcl-1 is mediated by activa-
tion of extracellular signal-regulated kinase (ERK) and phos-
phatidylinositol 3-kinase (PI3K) [11]. However, activation of
ERK and PI3K is unlikely to be involved in cAMP-mediated
stabilization of Mcl-1, since ERK, PI3K, p38, Akt, IjB,
STAT3 and STAT5 were not phosphorylated in neutrophils
treated with cAMP agonists (data not shown). In addition,
Mcl-1 is unlikely to be hyperphosphorylated in neutrophils
treated with cAMP agonists, since the mobility shift of the
Mcl-1 band was not observed in these cells (Fig. 2).4. Discussion
Most previous studies have focused the induction of anti-
apoptotic molecules at the transcriptional level as a mechanism
for delayed neutrophil apoptosis. In fact, the anti-apoptotic ef-
fects of physiologically important cytokines such as G-CSF
and GM-CSF are markedly inhibited by cycloheximide and
actinomycin D, and several anti-apoptotic molecules, includ-
ing Mcl-1, cIAP2, survivin and A1, have been demonstrated
to be induced by stimulation with G-CSF or GM-CSF [1–
4,7,8]. These anti-apoptotic molecules may play an important
role in cytokine-mediated anti-apoptotic eﬀect on neutrophils.
By contrast, cAMP-mediated anti-apoptotic eﬀect was highly
resistant to cycloheximide, suggesting that the stabilization
Fig. 5. Combination of dibutyryl cAMP and proteasome inhibitors
exerts no additive eﬀect on prevention of Mcl-1 degradation. Neutro-
phils were incubated in the presence or absence of dibutyryl cAMP
(db-cAMP, 1 mM), epoxomicin (1 lM), lactacystin (5 lM), or combi-
nation of these agents for 8 h at 37 C. Immunoblotting was performed
using antibodies against Mcl-1 and p38, which was used as control.
The cell lysates equivalent to 5 · 105 cells were loaded onto each lane.
The results shown are representative of three independent experiments
(upper panel). The densitometric data are expressed as means ± S.E.M.
of three independent experiments (lower panel). The ratio of Mcl-1 to
p38 band intensity was calculated, and the ratio at hour 0 is expressed
as 1. +Signiﬁcantly decreased as compared with 0 h controls (P < 0.01).
*Mcl-1 degradation was signiﬁcantly prevented by dibutyryl cAMP,
epoxomicin, lactacystin, or combination of these agents (P < 0.01).
Fig. 4. Combination of dibutyryl cAMP and proteasome inhibitors
exerts no additive eﬀect on prevention of neutrophil apoptosis.
Neutrophils were incubated in the presence or absence of dibutyryl
cAMP (db-cAMP, 1 mM), epoxomicin (1 lM), lactacystin (5 lM), or
combination of these agents for 8 h at 37 C. Apoptotic cells were
analyzed by ﬂow cytometry. The data are expressed as means ± S.E.M.
of three independent experiments. +Signiﬁcantly greater as compared
with 0 h controls (P < 0.01). *Spontaneous apoptosis was signiﬁcantly
prevented by dibutyryl cAMP, epoxomicin, lactacystin, or combina-
tion of these agents (P < 0.01).
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process. Among anti-apoptotic molecules studied, only Mcl-1
was degraded during spontaneous neutrophil apoptosis, and
Mcl-1 was stabilized by cAMP agonists and proteasome inhib-
itors with concomitant delay of neutrophil apoptosis. It is pos-
sible that induced expression of Mcl-1 mRNA may partly
contribute to cAMP-mediated anti-apoptotic eﬀect, since our
previous study shows that the protein-synthesis dependent
mechanism is also partly involved in cAMP-mediated anti-
apoptotic eﬀect and this mechanism is apparent after pro-
longed incubation (more than 9 h) [4].
The mechanism by which cAMP agonists stabilize Mcl-1 re-
mains to be determined. ERK and PI3K are unlikely to be in-
volved in this process, although both molecules are reported to
be involved in GM-CSF-mediated stabilization of Mcl-1 [11].
Accumulated evidences indicate that PKA is involved in
cAMP-mediated anti-apoptotic eﬀect on human neutrophils
[5,10,12,13]. A possibility is that PKA phosphorylates speciﬁc
residues of Mcl-1, leading to stabilization of this molecule. In
fact, PKA-mediated promotion and inhibition of protein deg-
radation by the proteasome have been demonstrated. For
example, PKA stabilizes RhoA by phosphorylating RhoA at
Ser188, and PKA inhibits the ubiquitination of b-catenin
by phosphorylating b-catenin, thereby causing b-catenin to
accumulate [14,15]. On the other hand, PKA-mediated phos-
phorylation of glucocorticoid receptor-interacting protein 1
promotes degradation of this protein [16], and hyperphosph-
orylation of Mcl-1 appears to promote degradation of this pro-tein [11]. Mcl-1 possesses many phosphorylation sites, and it is
likely that diﬀerential phosphorylation of Mcl-1 results in dif-
ferent fate of this protein. On the standpoint of therapeutics, it
is important to determine whether cAMP agonists also stabi-
lize Mcl-1 in other types of primary cells and malignant cells;
in particular, malignant cells such as chronic lymphocytic leu-
kemia cells and myeloma cells, in which Mcl-1 is overexpressed
[17,18]. In any case, the present experiments demonstrate that
cAMP agonists, physiologically important inﬂammatory medi-
ators, may exert the anti-apoptotic eﬀect on human neutro-
phils primarily via stabilization of Mcl-1, a diﬀerent way
from cytokine-mediated anti-apoptotic eﬀect.
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